Physician profile
Rojay Rinaldo Passley
NPI 1497321483
$3,714.13
in general payments reported to CMS, 2019-2025
19 companies · $899 in 2025
The $899 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,528 · 2024: $1,287 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.29 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $665.95 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $609.99 | 2023-2025 | Caplyta |
| Abbvie INC. | $555.02 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $435.60 | 2023-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $314.12 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $218.51 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $202.52 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $184.22 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $89.75 | 2023-2024 | Austedo Xr, Uzedy |
| Tris Pharma INC | $87.75 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $69.25 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $50.68 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $49.06 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $40.48 | 2024 | Cobenfy |
| Almatica Pharma LLC | $35.01 | 2024 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $31.37 | 2024-2025 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $30.41 | 2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $30.03 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $14.41 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rojay Passley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.